Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
Open Access
- 29 June 2022
- journal article
- research article
- Published by IOS Press in Journal of Alzheimer's Disease
- Vol. 88 (4), 1459-1468
- https://doi.org/10.3233/jad-220323
Abstract
Background: Phosphatidylethanolamine binding protein 1 (PEBP1) is a multifunctional protein, mainly known for its specific binding of phosphatidylethanolamine and the ability to suppress the Raf1-MAPK pathway. Its potential role as an Alzheimer’s disThis publication has 32 references indexed in Scilit:
- The Reactome pathway knowledgebaseNucleic Acids Research, 2013
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersThe Lancet Neurology, 2013
- Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical LiteratureCold Spring Harbor Perspectives in Medicine, 2011
- Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairmentActa Neuropathologica, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- A consensus protocol for the standardization of cerebrospinal fluid collection and biobankingNeurology, 2009
- Downregulation of PEBP1 in Rat Brain Cortex in HypoxiaJournal of Molecular Neuroscience, 2009
- Alzheimer's diseaseThe Lancet, 2006
- Decreased phosphatidylethanolamine binding protein expression correlates with Aβ accumulation in the Tg2576 mouse model of Alzheimer's diseaseNeurobiology of Aging, 2006
- High levels of hippocampal cholinergic neurostimulating peptide (HDNP> in the CSF of some patients with Alzhemer's diseaseEuropean Journal of Neurology, 1998